Novartis Snaps Up Cachexia Candidate On The Cheap As AVEO's Focus Returns to Tivozanib

AVEO Oncology is seeing the resurgence in its fortunes continue with the signing of a licensing agreement with Novartis for its growth differentiation factor 15 (GDF15) inhibitory antibody AV-380, which is in preclinical development as a potential treatment for cachexia.

AVEO Oncology is seeing the resurgence in its fortunes continue with the signing of a licensing agreement with Novartis for its growth differentiation factor 15 (GDF15) inhibitory antibody AV-380, which is in preclinical development as a potential treatment for cachexia.

The company's share price had almost doubled to $2.30 within 30 minutes of the markets opening (17 August).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.